Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn)

Type: drug

Status: FDA Approved

Developer: Regeneron Pharmaceuticals

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026